All Title Author
Keywords Abstract

PLOS ONE  2011 

Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy

DOI: 10.1371/journal.pone.0029052

Full-Text   Cite this paper   Add to My Lib

Abstract:

Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in young and non-obese PCOS women. However, the metabolic processes involved in this phenotypic amelioration remain unidentified. In this work, we used NMR and MS-based untargeted metabolomics to study serum samples of young non-obese PCOS women prior to and at the end of a 30 months polytherapy receiving low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen. Our results reveal that the treatment decreased the levels of oxidized LDL particles in serum, as well as downstream metabolic oxidation products of LDL particles such as 9- and 13-HODE, azelaic acid and glutaric acid. In contrast, the radiuses of small dense LDL and large HDL particles were substantially increased after the treatment. Clinical and endocrine-metabolic markers were also monitored, showing that the level of HDL cholesterol was increased after the treatment, whereas the level of androgens and the carotid intima-media thickness were reduced. Significantly, the abundance of azelaic acid and the carotid intima-media thickness resulted in a high degree of correlation. Altogether, our results reveal that this new polytherapy markedly reverts the oxidant status of untreated PCOS women, and potentially improves the pro-atherosclerosis condition in these patients.

References

[1]  Ibanez L, Valls C, de Zegher F (2006) Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Human Reproduction 21: 451–456.
[2]  Lambrinoudaki I (2011) Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 68: 13–16.
[3]  McGowan M (2011) Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease. Current Treatment Options in Cardiovascular Medicine 1–13.
[4]  Macut D, Panidis D, Glisi? B, Spanos N, Petakov M (2008) Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 86: 199–204.
[5]  Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, et al. (2006) Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155: 131–136.
[6]  Sabuncu T, Vural H, Harma M, Harma M (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clinical Biochemistry 34: 407–413.
[7]  Wild RA (2002) Long-term health consequences of PCOS. Human Reproduction Update 8: 231–241.
[8]  Legro RS (2003) Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? Endocrine Reviews 24: 302–312.
[9]  Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, et al. (2004) Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 5454–5461.
[10]  Ibanez L, Lopez-Bermejo A, del Rio L, Enriquez G, Valls C, et al. (2007) Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. Journal Of Clinical Endocrinology And Metabolism 92: 1710–1714.
[11]  Ibanez L, Lopez-Bermejo A, Diaz M, Enriquez G, Valls C, et al. (2008) Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clinical Endocrinology 68: 317–320.
[12]  Ibá?ez L, López-Bermejo A, Díaz M, Enríquez G, Del Río L, et al. (2009) Low-dose pioglitazone and low-dose flutamide added to metformin and estro-progestagens for hyperinsulinemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol 71: 351–357.
[13]  Iba?ez L, López-Bermejo A, Díaz M, Enríquez G, Del Río L, et al. (2010) Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecological Endocrinology 26: 869–873.
[14]  Lenz EM, Bright J, Knight R, Wilson ID, Major H (2004) Cyclosporin A-induced changes in endogenous metabolites in rat urine: A metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. Journal of Pharmaceutical and Biomedical Analysis 35: 599–608.
[15]  Sieber M, Wagner S, Rached E, Amberg A, Mally A, et al. (2009) Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem Res Toxicol 22: 1221–1231.
[16]  Williams R, Lenz EM, Wilson AJ, Granger J, Wilson ID, et al. (2006) A multi-analytical platform approach to the metabonomic analysis of plasma from normal and zucker (fa/fa) obese rats. Molecular BioSystems 2: 174–183.
[17]  Dunn WB, Bailey NJC, Johnson HE (2005) Measuring the metabolome: current analytical technologies. Analyst 130: 606–625.
[18]  Moco S, Vervoort J, Moco S, Bino RJ, De Vos RCH, et al. (2007) Metabolomics technologies and metabolite identification. TrAC Trends in Analytical Chemistry 26: 855–866.
[19]  Lenz EM, Wilson ID (2006) Analytical Strategies in Metabonomics. Journal of Proteome Research 6: 443–458.
[20]  Dunn WB, Ellis DI (2005) Metabolomics: Current analytical platforms and methodologies. TrAC Trends in Analytical Chemistry 24: 285–294.
[21]  Mallol R, Rodríguez M, Heras M, Vinaixa M, Ca?ellas N, et al. (2011) Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for human plasma lipoproteins characterization. Metabolomics 1–11.
[22]  Palazoglu M, Fiehn O (2009) Metabolite Identification in Blood Plasma Using GC/MS and the Agilent Fiehn GC/MS Metabolomics RTL Library. Agilent Application Note.
[23]  Jansen JJ, Hoefsloot HCJ, van der Greef J, Timmerman ME, Smilde AK (2005) Multilevel component analysis of time-resolved metabolic fingerprinting data. Analytica Chimica Acta 530: 173–183.
[24]  Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G (2006) XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification. Analytical Chemistry 78: 779–787.
[25]  Jankowski J, Nofer JR, Tepel M, Griewel B, Schl?ter H, et al. (1998) Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci 95: 489–495.
[26]  Lee SH, Blair IA (2001) Oxidative DNA Damage and Cardiovascular Disease. Trends in Cardiovascular Medicine 11: 148–155.
[27]  Lee SH, Williams MV, Blair IA (2005) Targeted chiral lipidomics analysis. Prostaglandins & Other Lipid Mediators 77: 141–157.
[28]  Palinski W, Rosenfeld ME, Yl?-Herttuala S, Gurtner GC, Socher SS, et al. (1989) Low density lipoprotein undergoes oxidative modification in vivo. Proceedings of the National Academy of Sciences of the United States of America 86: 1372–1376.
[29]  Haberland ME, Olch CL, Folgelman AM (1984) Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. Journal of Biological Chemistry 259: 11305–11311.
[30]  Raghavamenon A, Garelnabi M, Babu S, Aldrich A, Litvinov D, et al. (2009) Alpha-Tocopherol Is Ineffective in Preventing the Decomposition of Preformed Lipid Peroxides and May Promote the Accumulation of Toxic Aldehydes: A Potential Explanation for the Failure of Antioxidants to Affect Human Atherosclerosis. Antioxidants & Redox Signaling 11: 1237–1248.
[31]  Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW (2005) Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res 46: 1440–1449.
[32]  Tokumura A, Toujima M, Yoshioka Y, Fukuzawa K (1996) Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids 31: 1251–1258.
[33]  Chen R, Yang L, McIntyre TM (2007) Cytotoxic Phospholipid Oxidation Products. Journal of Biological Chemistry 282: 24842–24850.
[34]  Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR (2005) Lipid-Derived Modifications of Plasma Proteins in Experimental and Human Diabetes. Annals of the New York Academy of Sciences 1043: 404–412.
[35]  Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, et al. (2000) Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. Clinical Therapeutics 22: 1395–1409.
[36]  Charbonnel B, Schernthaner G, Brunetti P, Matthews D, Urquhart R, et al. (2005) Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48: 1093–1104.
[37]  Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. (2006) Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics 31: 375–383.
[38]  Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. (2007) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 37: 79–86.
[39]  Hanefeld M (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11: 742–756.
[40]  Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD (2004) Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes. Diabetes Care 27: 41–46.
[41]  Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, et al. (2003) Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension. Diabetes Care 26: 2588–2594.
[42]  Iida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, et al. (2003) Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. American Journal of Physiology - Endocrinology And Metabolism 284: E1125–E1130.
[43]  Steinberg D (1990) Arterial Metabolism of Lipoproteins in Relation to Atherogenesis. Annals of the New York Academy of Sciences 598: 125–135.

Full-Text

comments powered by Disqus